SG118236A1 - Compositions and methods for treating coronavirus infection and SARS - Google Patents
Compositions and methods for treating coronavirus infection and SARSInfo
- Publication number
- SG118236A1 SG118236A1 SG200401808A SG200401808A SG118236A1 SG 118236 A1 SG118236 A1 SG 118236A1 SG 200401808 A SG200401808 A SG 200401808A SG 200401808 A SG200401808 A SG 200401808A SG 118236 A1 SG118236 A1 SG 118236A1
- Authority
- SG
- Singapore
- Prior art keywords
- sars
- compositions
- methods
- coronavirus infection
- treating coronavirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04G—SCAFFOLDING; FORMS; SHUTTERING; BUILDING IMPLEMENTS OR AIDS, OR THEIR USE; HANDLING BUILDING MATERIALS ON THE SITE; REPAIRING, BREAKING-UP OR OTHER WORK ON EXISTING BUILDINGS
- E04G19/00—Auxiliary treatment of forms, e.g. dismantling; Cleaning devices
- E04G19/006—Cleaning devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Architecture (AREA)
- Structural Engineering (AREA)
- Civil Engineering (AREA)
- Mechanical Engineering (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45978303P | 2003-04-01 | 2003-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG118236A1 true SG118236A1 (en) | 2006-01-27 |
Family
ID=33551338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200401808A SG118236A1 (en) | 2003-04-01 | 2004-04-01 | Compositions and methods for treating coronavirus infection and SARS |
Country Status (9)
Country | Link |
---|---|
US (2) | US20050002901A1 (ja) |
EP (1) | EP1651271A4 (ja) |
JP (1) | JP2006528679A (ja) |
KR (1) | KR20040088393A (ja) |
CN (1) | CN1533808A (ja) |
CA (1) | CA2520148A1 (ja) |
SG (1) | SG118236A1 (ja) |
TW (1) | TW200500079A (ja) |
WO (1) | WO2004110392A2 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050137154A1 (en) * | 2003-05-16 | 2005-06-23 | Hemispherx Biopharma | Treating server acute respiratory syndrome |
US20060035859A1 (en) * | 2003-05-16 | 2006-02-16 | Hemispherx Biopharma | Treating severe and acute viral infections |
WO2004100980A1 (en) * | 2003-05-19 | 2004-11-25 | Viragen, Inc. | Interferon for treating or preventing a coronaviral infection |
JP2006527268A (ja) * | 2003-06-09 | 2006-11-30 | ゲノム インスティチュート オブ シンガポール | 臨床的に認められた抗ウイルス剤を用いるsarsコロナウイルス感染の阻害 |
WO2005123113A2 (en) * | 2004-06-14 | 2005-12-29 | Intermune, Inc. | Interferon compositions and methods of use thereof |
CN101437534A (zh) * | 2006-03-08 | 2009-05-20 | 半球生物制药公司 | 口服干扰素的广谱免疫和抗病毒基因调节作用 |
US8075877B2 (en) | 2006-03-08 | 2011-12-13 | Hemispherx Biopharma | Broad spectrum immune and antiviral gene modulation by oral interferon |
MX2022009712A (es) * | 2020-02-06 | 2022-09-09 | Eiger Biopharmaceuticals Inc | Tratamiento de infeccion por coronavirus con interferon lambda. |
CN111346219B (zh) * | 2020-02-21 | 2021-05-14 | 上海甘翼生物医药科技有限公司 | 干扰素在制备预防冠状病毒感染或预防冠状病毒感染引发的疾病的药物中的用途 |
CN113425832A (zh) * | 2020-03-23 | 2021-09-24 | 杭州先为达生物科技有限公司 | 干扰素λ在新型冠状病毒(2019-nCoV)感染治疗中的应用 |
US20230172885A1 (en) * | 2020-05-13 | 2023-06-08 | The Regents Of The University Of California | Thiol-containing compounds for use in treating coronavirus |
CN113813375B (zh) * | 2020-06-19 | 2023-06-16 | 杭州星鳌生物科技有限公司 | 一种新型抗新冠病毒复合物的组成及其在防治冠状病毒感染疾病药物中的应用 |
US20220040265A1 (en) * | 2020-08-07 | 2022-02-10 | Peter G. Carroll | Compositions and methods for preventing and/or inhibiting viral infection and spread |
CN116685598A (zh) * | 2020-09-24 | 2023-09-01 | 南湖制药公司 | 干扰素taufc-融合蛋白和治疗方法冠状病毒感染 |
WO2022187702A1 (en) * | 2021-03-05 | 2022-09-09 | Philera New Zealand | Prevention and treatment of coronavirus and related respiratory infections |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2172288T3 (es) * | 1998-05-15 | 2002-09-16 | Schering Corp | Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c. |
JP2002220343A (ja) * | 2001-01-26 | 2002-08-09 | Toray Ind Inc | びまん性肺疾患延命剤 |
KR20060020610A (ko) * | 2003-04-08 | 2006-03-06 | 코로노바티브 비.브이. | 사스 |
KR20050112127A (ko) * | 2003-04-17 | 2005-11-29 | 아레스 트레이딩 에스.에이. | 중증급성호흡기증후군(sars)에 인터페론 베타 |
CN1449740A (zh) * | 2003-05-14 | 2003-10-22 | 长春长生基因药业股份有限公司 | 具有杀灭病毒作用的α干扰素系列药物化妆品 |
JP2006527268A (ja) * | 2003-06-09 | 2006-11-30 | ゲノム インスティチュート オブ シンガポール | 臨床的に認められた抗ウイルス剤を用いるsarsコロナウイルス感染の阻害 |
-
2004
- 2004-03-12 CA CA002520148A patent/CA2520148A1/en not_active Abandoned
- 2004-03-12 WO PCT/US2004/007819 patent/WO2004110392A2/en not_active Application Discontinuation
- 2004-03-12 EP EP04749378A patent/EP1651271A4/en not_active Withdrawn
- 2004-03-12 JP JP2006532325A patent/JP2006528679A/ja not_active Withdrawn
- 2004-03-26 TW TW093108408A patent/TW200500079A/zh unknown
- 2004-03-30 US US10/814,701 patent/US20050002901A1/en not_active Abandoned
- 2004-04-01 CN CNA2004100324420A patent/CN1533808A/zh active Pending
- 2004-04-01 SG SG200401808A patent/SG118236A1/en unknown
- 2004-04-01 KR KR1020040022531A patent/KR20040088393A/ko not_active Application Discontinuation
-
2008
- 2008-07-29 US US12/181,873 patent/US20090068142A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
CHICKEN INTERFERON TYPE 1 INHIBITS INFECTIOUS BRONCHITIS VIRUS REPUBLICATION AND ASSOCIATED RESPIRATORY. * |
SYNERGISTIC ANTIVIRAL EFFECT OF A COMBINATION OF MOUSE INTERFERON-X AND INTERFERON-Y ON MOUSE HEPATITIS VIRUS. * |
Also Published As
Publication number | Publication date |
---|---|
CA2520148A1 (en) | 2004-12-23 |
EP1651271A4 (en) | 2006-11-08 |
WO2004110392A3 (en) | 2005-06-30 |
KR20040088393A (ko) | 2004-10-16 |
TW200500079A (en) | 2005-01-01 |
JP2006528679A (ja) | 2006-12-21 |
US20090068142A1 (en) | 2009-03-12 |
US20050002901A1 (en) | 2005-01-06 |
EP1651271A2 (en) | 2006-05-03 |
CN1533808A (zh) | 2004-10-06 |
WO2004110392A2 (en) | 2004-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2089A (en) | Compositions and methods for combination antiviraltherapy | |
PT3006040T (pt) | Métodos e composições para o tratamento de neuropatias | |
HK1074005A1 (en) | Compositions and methods for treating or preventing pneumococcal infection | |
ZA200600384B (en) | Compositions and methods for increasing bone mineralization | |
GB0411940D0 (en) | Methods and compositions | |
EP1696897A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES | |
EP1701725A4 (en) | PROCESS AND COMPOSITIONS | |
EP1755537A4 (en) | METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA | |
AU2003239129A8 (en) | Methods and compositions for dna manipulation | |
EP1468118A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
ZA200602738B (en) | Methods and compositions for treating herpes infections | |
SG118236A1 (en) | Compositions and methods for treating coronavirus infection and SARS | |
GB0303609D0 (en) | Novel therapeutic method and compositions | |
EP1461047A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ANIMALS | |
AU2003296963A8 (en) | Methods and compositions for treating and preventing ear infections | |
EP1626711A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
AU2003259202A8 (en) | Compositions and methods for treating and preventing infection | |
GB0324523D0 (en) | Compositions and methods of treatment | |
AU2003275069A8 (en) | Compositions and methods for preventing infection | |
AU2003303948A8 (en) | Compositions and methods for preventing infection | |
AU2003298708A8 (en) | Gpc99 and gpc99a: methods and compositions for treating cancer | |
HK1079693A1 (en) | Compositions for treating and/or preventing pollenosis | |
EP1599214A4 (en) | METHODS AND COMPOSITIONS FOR TREATING UTERINE COLON CANCER | |
GB0303600D0 (en) | Novel therapeutic method and compositions | |
IL163878A0 (en) | Compositions and methods for treating mdma-inducedtoxicity |